Real-world adoption of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer highlights ongoing gaps in homologous recombination (HR) biomarker testing across prostate cancer care.
Andrew Osterland, PharmD
Advertisement
Articles by Andrew Osterland, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5